EFFICACY AND FREQUENCY OF INTRAVITREAL AFLIBERCEPT VERSUS BEVACIZUMAB FOR MACULAR EDEMA SECONDARY TO CENTRAL RETINAL VEIN OCCLUSION
Authors:
- Kamal A. M. SolaimanKSKamal A. M. Solaiman
- Ayman AbdelrahmanAAAyman Abdelrahman
- Ahmed SamirASAhmed Samir
- 1 September 2018
- journal article
- research article
- Published by Wolters Kluwer Health in Retina
- Vol. 38 (9) , 1795-1800
Abstract
Purpose: To compare the safety, efficacy, and frequency of intravitreal injection of aflibercept and bevacizumab for treatment of macular edema secondary to central retinal vein occlusion. Design: Prospective, comparative, randomized, interventional study. Patients and Methods: Eyes with macular edema secondary to central retinal vein occlusion were randomized between two groups according to the intravitreal injection used. Group A included eyes treated with intravitreal aflibercept, and Group B included eyes treated with intravitreal bevacizumab injections. The inclusion criteria were macular edema secondary to central retinal vein occlusion and follow-up duration of at least 12 months after the first injection. Exclusion criteria were macular ischemia, associated diabetes, hypertensive or renal retinopathy, other retinal disease, and previous anti–vascular endothelial growth factor injection. The main outcome measures are central foveal thickness, best-corrected visual acuity, time intervals between injections, improved retinal nonperfusion, and any reported complication. Results: Group A included 39 patients with a mean age of 57.4 ± 8.2 years. Group B included 40 eyes with a mean age of 56.5 ± 9.1 years. Twelve months after the first injection, central foveal thickness significantly improved from 475.45 ± 71.05 m to 259.11 ± 20.67 m in Group A and from 460.22 ± 89.38 m to 264.29 ± 32.05 m in Group B; best-corrected visual acuity significantly improved from 0.81 ± 0.16 logarithm of the minimum angle of resolution (20/125) to 0.34 ± 0.14 logarithm of the minimum angle of resolution (20/40) in Group A and from 0.73 ± 0.15 logarithm of the minimum angle of resolution (20/100) to 0.33 ± 0.17 logarithm of the minimum angle of resolution (20/40) in Group B; the mean number of injections was 3.72 ± 2.93 in Group A and was 5.44 ± 2.85 in Group B (P < 0.05); and the mean interval between injections was 54.23 ± 8.47 days in Group A and was 35.12 ± 7.76 days in Group B (P < 0.05). Retinal nonperfusion improved in 9/12 eyes in Group A and in 3/8 eyes in Group B (P < 0.05). Conclusion: Both aflibercept and bevacizumab are comparably effective for treatment of macular edema secondary to central retinal vein occlusion without significant complications. However, the burden of frequent intravitreal injections could be significantly reduced when using aflibercept.Keywords
This publication has 14 references indexed in Scilit:
- Effect of aflibercept on refractory macular edema associated with central retinal vein occlusionCanadian Journal of Ophthalmology, 2016
- Intravitreal Aflibercept Injection for Macular Edema Due to Central Retinal Vein OcclusionOphthalmology, 2014
- Intravitreal Aflibercept Injection for Macular Edema Resulting from Central Retinal Vein OcclusionOphthalmology, 2014
- Intravitreal Aflibercept Injection for Macular Edema Secondary to Central Retinal Vein Occlusion: 1-Year Results From the Phase 3 COPERNICUS StudyAmerican Journal of Ophthalmology, 2013
- VEGF Trap-Eye for macular oedema secondary to central retinal vein occlusion: 6-month results of the phase III GALILEO studyBritish Journal of Ophthalmology, 2013
- Vascular Endothelial Growth Factor A in Intraocular Vascular DiseaseOphthalmology, 2013
- Role of soluble vascular endothelial growth factor receptor-2 in macular oedema with central retinal vein occlusionBritish Journal of Ophthalmology, 2010
- Ranibizumab for Macular Edema following Central Retinal Vein OcclusionOphthalmology, 2010
- Randomized, Sham-Controlled Trial of Dexamethasone Intravitreal Implant in Patients with Macular Edema Due to Retinal Vein OcclusionOphthalmology, 2010
- A Randomized Trial Comparing the Efficacy and Safety of Intravitreal Triamcinolone With Observation to Treat Vision Loss Associated With Macular Edema Secondary to Central Retinal Vein OcclusionArchives of Ophthalmology (1950), 2009